NASDAQ: TMDXTransmedics Group Inc Stock
$72.21+0.77 (+1.08%)
Updated Dec 4, 2024
TMDX Price
$72.21
Fair Value Price
N/A
Market Cap
$2.42B
52 Week Low
$68.84
52 Week High
$177.37
P/E
72.94x
P/B
11.54x
P/S
13.09x
PEG
1.97x
Dividend Yield
N/A
Revenue
$401.09M
Earnings
$32.64M
Gross Margin
59.3%
Operating Margin
11.74%
Profit Margin
8.1%
Debt to Equity
2.74
Operating Cash Flow
$37M
Beta
1.32
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TMDX Overview
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TMDX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
D
Momentum
F
Sentiment
D
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important TMDX news, forecast changes, insider trades & much more!
TMDX News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TMDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TMDX ($72.21) is trading above its intrinsic value of $18.48, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TMDX is poor value based on its earnings relative to its share price (72.94x), compared to the US market average (28.79x)
P/E vs Market Valuation
TMDX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more TMDX due diligence checks available for Premium users.
Valuation
TMDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
72.94x
Industry
37.49x
Market
28.79x
TMDX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TMDX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
TMDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.54x
Industry
4.1x
TMDX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TMDX price to earnings growth (PEG)
For valuing profitable companies with growth potential
TMDX is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
TMDX's financial health
Profit margin
Revenue
$108.8M
Net Income
$4.2M
Profit Margin
3.9%
TMDX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TMDX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$785.6M
Liabilities
$575.7M
Debt to equity
2.74
TMDX's short-term assets ($492.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TMDX's long-term liabilities ($515.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TMDX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TMDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$6.9M
Investing
-$47.8M
Financing
$7.9M
TMDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TMDX vs Medical Device Stocks
Transmedics Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.